Arbor Pharmaceuticals launches new nonantibiotic product for ear infections

Xylarex is a novel oral solution intended to be administered daily to reduce the number of ear infections children experience. The primary ingredient in Xylarex has also been shown to reduce the amount of antibiotics prescribed to children affected by middle ear infections. Xylarex can be administered to children as young as six months of age.

Xylarex is available by prescription and can be obtained from retail pharmacies across the US. Xylarex is being introduced to US pediatricians by Arbor Pharmaceuticals’s specialty sales force.

Jarrett Disbrow, president and CEO of Arbor, said: “Xylarex is a very important product as it represents a non-drug therapy with the potential to positively impact the lives of millions of children suffering from recurrent ear infections. Arbor is firmly dedicated to health of children, and Xylarex will be a significant addition for the management of common ear infections.”